Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

$ USD

You are here:Home-Research Areas-Other Indications-Steatohepatitis

Request The Product List ofSteatohepatitis Steatohepatitis

   Steatohepatitis is one type of liver disease which can be characterized by the inflammation and fat accumulation of liver which is a part of the alcoholic liver disease. It is otherwise called as fatty liver disease.


   Type:

 ~Nonalcoholic Steatohepatitis(NASH)

 ~Alcoholic Steatohepatitis(ASH)

Cat. No. Product Name CAS No. Information
GY03950

MGL-3196

920509-32-6

MGL-3196 (VIA-3196, Resmetirom) is a potent and highly selective agonist of THR-β (Thyroid Hormone Receptor β) with EC50 of 0.21 uM; shows 28-fold selectivity for THR-β over THR-α in a functional assay; exhibits an excellent safety profile and orally bioactive.

GY10353

Apararenone

945966-46-1

Apararenone (MT-3995) is a novel potent, selective non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

GY04721

Lanifibranor

927961-18-0

IVA-337 (Lanifibranor, IVA337)) is a potent, pan PPAR agonist with EC50 of 0.92 uM, 0.53 uM and 0.18 uM for human PPARα, PPARδ and PPARγ respectively; reduces skin fibrosis in the mouse, and suppresses inflammation in vivo.

GY03441

Oltipraz

64224-21-1

Oltipraz (RP 35972, NSC 347901) is a cancer chemopreventive agent with inhibitory effect on angiogenesis and tumor growth, inhibits insulin- or hypoxia-induced HIF-1α expression through an increase in ubiquitination; abrogates insulin-induced H(2)O(2) production, thereby preventing H(2)O(2)-enhanced HIF-1alpha expression and promoting its ubiquitination and degradation; inhibits HIF-1α activity and HIF-1α-dependent tumor growth both in vitro and in vivo.

GY04686

Tropifexor

1383816-29-2

Tropifexor (LJN-452, LJN452) is a novel highly potent, selective, orally acitive FXR full agonist with EC50 of 0.26 nM; shows no significant off-target activity (>10,000-fold selectivity for FXR) in a panel of targets, including TGR5 (>10 uM); demonstratesin vivo activity in rodent PD models, and shows potential for treatment of cholestatic liver diseases and NASH.

GY06417

Cilofexor

1418274-28-8

Cilofexor (GS-9674, GS9674, PX-104) is a novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.

GY01243

Emricasan

254750-02-2

Emricasan (IDN-6556;PF-03491390) is a potent, irreversible pan-caspase inhibitor, shows neuroprotective activity for hNPCs, inhibits ZIKV-induced increased caspase-3 activity.

GY01190

Selonsertib

1448428-04-3

Selonsertib (GS-4997) is a highly selective and potent, ATP-competetive inhibitor of ASK1 (Apoptosis Signal-regulating Kinase 1, MAP3K5) with potential anti-inflammatory, antineoplastic and anti-fibrotic activities; orally bioavailable.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use